Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) saw a large increase in short interest during the month of December. As of December 15th, there was short interest totalling 22,900 shares, an increase of 340.4% from the November 30th total of 5,200 shares. Based on an average trading volume of 74,100 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.3% of the company's shares are short sold.
Institutional Investors Weigh In On Avalo Therapeutics
Institutional investors and hedge funds have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new stake in shares of Avalo Therapeutics in the 3rd quarter valued at about $9,186,000. Ikarian Capital LLC raised its stake in Avalo Therapeutics by 1,673.0% in the 3rd quarter. Ikarian Capital LLC now owns 970,359 shares of the company's stock worth $9,218,000 after purchasing an additional 915,629 shares in the last quarter. Logos Global Management LP acquired a new stake in Avalo Therapeutics during the second quarter worth approximately $6,722,000. Finally, Affinity Asset Advisors LLC grew its holdings in shares of Avalo Therapeutics by 350.0% during the 2nd quarter. Affinity Asset Advisors LLC now owns 45,000 shares of the company's stock worth $561,000 after purchasing an additional 35,000 shares in the last quarter. Institutional investors own 87.06% of the company's stock.
Avalo Therapeutics Stock Up 3.2 %
Avalo Therapeutics stock traded up $0.28 during mid-day trading on Thursday, reaching $9.09. The company's stock had a trading volume of 94,826 shares, compared to its average volume of 204,228. The business's 50 day simple moving average is $11.07 and its 200 day simple moving average is $10.69. Avalo Therapeutics has a 12 month low of $3.95 and a 12 month high of $34.46.
Wall Street Analyst Weigh In
A number of research analysts recently issued reports on AVTX shares. BTIG Research initiated coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They set a "buy" rating and a $40.00 price objective for the company. HC Wainwright started coverage on shares of Avalo Therapeutics in a report on Thursday, October 24th. They set a "neutral" rating on the stock.
Get Our Latest Stock Analysis on Avalo Therapeutics
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Further Reading
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
